AstraZeneca Gets Stake In CAT Through $175M Antibody Deal

LONDON - Cambridge Antibody Technology Group plc committed its future to a five-year deal with AstraZeneca plc, in which the partners will invest $175 million to fund 25 antibody discovery programs and AstraZeneca will pay £75 million (US$139.1 million) to become CAT's largest shareholder at 19.9 percent. (BioWorld Today)